Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Lim

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Pharmacotherapy|October 4, 2003
Outcomes of dual-protease inhibitor salvage therapy in human immunodeficiency virus-infected patients referred to a telephone consultation serviceMichael L Lim, Betty J Dong, Stacey L Hart
The Annals of Pharmacotherapy|June 28, 2002
Kaletra (lopinavir/ritonavir)Amanda H Corbett, Michael L Lim, Angela D M Kashuba
HIV Clinical Trials|April 17, 2007
Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States citiesLisa Ross, Michael L Lim, Qiming Liao, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2004
Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 inductionMichael L Lim, Sherene S Min, Joseph J Eron, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2006
Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavirAmanda H Corbett, Kristine B Patterson, Hsiao-Chuan Tien, et al.
The Journal of Infectious Diseases|November 4, 2005
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjectsJoel E Gallant, Allan E Rodriguez, Winkler G Weinberg, et al.
Pharmacotherapy|February 26, 2008
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA studyCalvin J Cohen, Marshall Kubota, Philip S Brachman, et al.
HIV Clinical Trials|December 13, 2006
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infectionPeter Ruane, Joseph Lang, Edwin DeJesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2010
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT studyFrank A Post, Graeme J Moyle, Hans Jürgen Stellbrink, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pharmacotherapy|October 4, 2003
Outcomes of dual-protease inhibitor salvage therapy in human immunodeficiency virus-infected patients referred to a telephone consultation serviceMichael L Lim, Betty J Dong, Stacey L Hart
The Annals of Pharmacotherapy|June 28, 2002
Kaletra (lopinavir/ritonavir)Amanda H Corbett, Michael L Lim, Angela D M Kashuba
HIV Clinical Trials|April 17, 2007
Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States citiesLisa Ross, Michael L Lim, Qiming Liao, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2004
Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 inductionMichael L Lim, Sherene S Min, Joseph J Eron, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2006
Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavirAmanda H Corbett, Kristine B Patterson, Hsiao-Chuan Tien, et al.
The Journal of Infectious Diseases|November 4, 2005
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjectsJoel E Gallant, Allan E Rodriguez, Winkler G Weinberg, et al.
Pharmacotherapy|February 26, 2008
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA studyCalvin J Cohen, Marshall Kubota, Philip S Brachman, et al.
HIV Clinical Trials|December 13, 2006
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infectionPeter Ruane, Joseph Lang, Edwin DeJesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2010
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT studyFrank A Post, Graeme J Moyle, Hans Jürgen Stellbrink, et al.
Pageof 1